From the presentation it seems they have fewer adverse events than kite's car-t for sure. I wonder if the nil side effects in that study carries over to MS as well. I looked at the infusion days for the cancer trials they are more frequent than the MS trial, so if the cancer trials have low side effects then the MS trials should have even less?
They did not give any details on why there would be cost savings for them compared to current treatments; they only said that they could charge half to disrupt the current market and still make a nice profit. No matter how much price competition occurs, TGTX said they should have a big advantage with a one-hour infusion time for TG-1101 versus four hours for other treatments.
News 
Market Data 
Discover 
